NEW YORK, Sept. 20 – Sequenom and Gemini Genomics have completed their stock-for-stock merger that has been in the works since May, the companies announced on Thursday. 

Sequenom, based in San Diego, nabbed Gemini Genomics for an as-yet undisclosed amount in stock in an attempt to boost its drug-development and clinical capabilities. The total dollar amount of the deal, originally said to be about $238 million, "is an open issue at the moment," a Sequenom spokesman said.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

In PLOS this week: grey wolf population genomics, mutations associated with lung adenocarcinoma survival, and more.

An opinion piece at Bloomberg discusses China's stance on genomic research.

Genetic ancestry testing can affect a person's sense of identity, the New York Times Magazine writes.

Nebula Genomics is launching its genome sequencing service for free for people who provide certain information about themselves, the Boston Globe reports.